訊鳥軟件上市首日收漲50.75%,盤中最高漲超150%
uSMART盈立智投4月21日消息,週二美股,訊鳥軟件(IFBD)登陸納斯達克,首日開盤上漲75%,盤中最高漲超150%,並觸及向上熔斷,截至收盤,訊鳥軟件漲50.75%,報6.03美元,總市值1.52億美元。
uSMART盈立支持0費用美股打新,此次在盈立申購訊鳥軟件的客戶,全員獲得高分配,總獲配額度約95%。
訊鳥軟件是提供呼叫中心AI驅動或人工智能支持的SaaS解決方案供應商,其在專注於爲金融行業的客戶提供服務的同時,亦將業務發展至包括教育、公共服務、醫療保健和消費品等行業中。

圖片來源:訊鳥軟件官網
該公司聯席承銷商爲WestPark Capital和廣發證券(香港)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.